Washington, D.C. 20549






Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) April 22, 2022



(Exact name of registrant as specified in its charter)







(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


100 – 740 McCurdy Road, Kelowna, BC Canada


V1X 2P7

(Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code (250) 765-6424



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange on which registered

Common Stock, par value $0.001 per share

Warrants to Purchase Common Stock





The Nasdaq Capital Market

The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 8.01 Other Events


Non-Material Agreements


Lexaria Bioscience Corp. (“Lexaria”) has entered into a manufacturing operating agreement with BevNology LLC (“BevNology”) whereby BevNology will provide fee-based services for the production of DehydraTECH-enabled active pharmaceutical ingredients for Lexaria’s corporate clients.


Lexaria, via its wholly owned subsidiary Lexaria Hemp Corp., has also entered into an intellectual property license agreement with BevNology. Bevnology has been provided with global non-exclusive rights for a period of five years, subject to certain exceptions as noted below, to utilize DehydraTECH patented technology with hemp derived CBD containing less than 0.3% THC for bulk powders, bulk liquids and third party finished consumer products for certain royalty fees.  The global rights do not extend into the countries of Japan, the Republic of Korea or the People's Republic of China and BevNology will hold limited exclusive rights only in the United States and only with respect to bulk liquids with the maintenance of such exclusive rights being subject to a minimum fee.








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.






/s/ Chris Bunka


Chris Bunka


CEO, Principal Executive Officer




Date: June 22, 2022






Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Lexaria Bioscience Charts.
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Lexaria Bioscience Charts.